# Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.

Source: https://onco.cc/trials/nct05948943/  
OnCo record `nct05948943` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Alpelisib in childhood cancers, run by Novartis Pharmaceuticals, now recruiting.

## Summary

Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation. is a phase 2/3 interventional study registered as NCT05948943 by Novartis Pharmaceuticals, with 232 participants planned, started 2023-11-24 and due to reach its primary completion in 2028-05-31. Interventions recorded: Alpelisib and Placebo.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05948943
- Phase: 2/3
- Setting: A Two-stage Double-blind, Randomized, Placebo-controlled Study to Assess the Efficacy, Safety and Pharmacokinetics of Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
- Sponsor: Novartis Pharmaceuticals
- Enrolled: 232

## Sources

- ClinicalTrials.gov NCT05948943: https://clinicaltrials.gov/study/NCT05948943

## Connected records

- cancers: [Childhood cancers (all types)](https://onco.cc/cancers/childhood-cancers/)
- drugs: [Alpelisib](https://onco.cc/drugs/alpelisib/)
- companies: [Advanced Accelerator Applications (Novartis)](https://onco.cc/companies/advanced-accelerator-applications/)

---
JSON: https://onco.cc/api/v1/entities/nct05948943.json